QNRX
Quoin Pharmaceuticals, Ltd.
NASDAQ · Healthcare · Biotechnology · US
$7.26
−7.75%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -53.2%
- EBIT
- -51.7%
- EPS
- +94.3%
- Free cash flow
- -43.9%
- Operating cash flow
- -43.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +60.0%
Three-year CAGR
- Revenue
- —
- EBITDA
- -77.2%
- EBIT
- -71.0%
- Net income
- -76.3%
- EPS
- +99.5%
- Free cash flow
- -72.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026